Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (DFPH) Cost of Revenue (2021 - 2025)

Historic Cost of Revenue for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to $117.6 million.

  • Oncology Institute's Cost of Revenue rose 3753.9% to $117.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $149.0 million, marking a year-over-year decrease of 3520.73%. This contributed to the annual value of $186.9 million for FY2024, which is 323.89% up from last year.
  • Oncology Institute's Cost of Revenue amounted to $117.6 million in Q3 2025, which was up 3753.9% from $51.2 million recorded in Q2 2025.
  • Oncology Institute's Cost of Revenue's 5-year high stood at $117.6 million during Q3 2025, with a 5-year trough of -$66.9 million in Q4 2024.
  • Its 5-year average for Cost of Revenue is $39.2 million, with a median of $42.8 million in 2023.
  • Data for Oncology Institute's Cost of Revenue shows a peak YoY increase of 9024.27% (in 2024) and a maximum YoY decrease of 23833.43% (in 2024) over the last 5 years.
  • Quarter analysis of 5 years shows Oncology Institute's Cost of Revenue stood at $27.4 million in 2021, then surged by 40.34% to $38.4 million in 2022, then rose by 26.01% to $48.4 million in 2023, then plummeted by 238.33% to -$66.9 million in 2024, then skyrocketed by 275.84% to $117.6 million in 2025.
  • Its Cost of Revenue stands at $117.6 million for Q3 2025, versus $51.2 million for Q2 2025 and $47.1 million for Q1 2025.